

## **Kuros Biosciences to propose re-appointment of Chairman and Board Members at Annual General Meeting**

**Schlieren (Zurich), Switzerland, April 30, 2019** – Kuros Biosciences (SIX: KURN) will propose the re-appointment of Clemens van Blitterswijk as Chairman of the Board of Directors, at its 2019 Annual General Meeting on May 21, as well as the re-election of six other Board members.

Shareholder approval will be sought for the re-appointment of Clemens van Blitterswijk as Chairman, as well as the re-election of Leanna Caron, Gerhard Ries, Jason Hannon, Scott Bruder, Oliver Walker and Joost de Bruijn as members of the Board of Directors. The terms will continue until the following Annual General Meeting.

Christian Itin and Giacomo di Nepi will not stand for re-election, as they have heavy responsibilities elsewhere, both as CEOs of public companies.

Clemens van Blitterswijk, Chairman of Kuros, said: “We would like to extend our deepest thanks to Christian and Giacomo, who have both played an important role in the re-positioning of Kuros as we have focused on the development of innovative products for spinal fusion. Last year, we added two new Board members – Jason Hannon and Scott Bruder – to reflect our focus on the commercialization and development of Fibrin PTH. So with Christian and Giacomo opting not to stand for re-election, the Board now returns to its previous size.”

Documents for the AGM, including the Information Notice with a full agenda, will be made available online on April 30 at: <http://www.kuros.ch/investors>

### **For further information, please contact:**

Kuros Biosciences AG

Michael Grau

Chief Financial Officer

Tel +41 44 733 47 47

[michael.grau@kurosbio.com](mailto:michael.grau@kurosbio.com)

LifeSci Advisors

Hans Herklots

Media & Investors

+41 79 598 7149

[hherklots@lifesciadvisors.com](mailto:hherklots@lifesciadvisors.com)

### **About Kuros Biosciences AG**

*Kuros Biosciences is focused on the development of innovative products for tissue repair and regeneration and is located in Schlieren (Zurich), Switzerland, Bilthoven, The Netherlands and Burlington (MA), U.S.A. The Company is*

listed according to the International Financial Reporting Standard on the SIX Swiss Exchange under the symbol KURN. Visit [www.kurosbio.com](http://www.kurosbio.com) for additional information on Kuros, its science and product pipeline.

**Forward Looking Statements**

*This media release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. You are urged to consider statements that include the words “will” or “expect” or the negative of those words or other similar words to be uncertain and forward-looking. Factors that may cause actual results to differ materially from any future results expressed or implied by any forward-looking statements include scientific, business, economic and financial factors, Against the background of these uncertainties, readers should not rely on forward-looking statements. The Company assumes no responsibility for updating forward-looking statements or adapting them to future events or developments.*